Novartis: Strong Execution With A P/E Discount
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
pharmaphorum2d
Novartis cues up Cosentyx as disease-modifying treatment for psoriasis
Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...
pharmaphorum1d
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...
BioSpace3d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
BioSpace5d
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
Personalized Medicine Biomarkers Market Size to Hit USD 58.39 Billion by 2032, Growing at a 14.54% CAGR – SNS Insider
Rising Demand for Precision Medicine and Advancements in Genomic Technologies Drive Market GrowthPune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Personalized Medicine Biomarkers ...
Hosted on MSN2d
The Surprising Way Cyndi Lauper Found Psoriasis Relief
Cyndi Lauper has never been one to back down. From shattering music industry norms with her trailblazing debut album, She's ...
BioPharma Dive4d
Jacob Bell
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.